{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T08:08:46Z","timestamp":1790842126893,"version":"4.1.0"},"reference-count":7,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T00:00:00Z","timestamp":1703116800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,1,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Only 30% of patients with McCune\u2013Albright syndrome (MAS)\u2013associated acromegaly achieve biochemical control under first-generation somatostatin receptor ligands (fg-SRLs), while pegvisomant fails to normalize insulin-like growth factor 1 (IGF-I) in &amp;gt;20% of cases. Here, we report all the patients with MAS-associated acromegaly treated with pasireotide long-acting release (LAR) in our center. Pasireotide LAR 20\u2005mg\/month resulted in rapid and long-term IGF-I normalization in patients #1 and #3. Patient #3 was resistant to fg-SRLs, while patient #1 was also controlled on fg-SRLs. In patient #2, resistant to fg-SRLs and uncontrolled on pegvisomant 40\u2005mg\/day combined with cabergoline 0.5\u2005mg\/day, pegvisomant was replaced with pasireotide LAR 40\u2005mg\/month, resulting in the near normalization of IGF-I levels. All 3 patients developed intermittent impaired fasting glucose, without the need for glucose-lowering drugs. Thus, pasireotide LAR is clearly useful as third-line therapy, and potentially even as second-line therapy, in MAS-associated acromegaly.<\/jats:p>","DOI":"10.1093\/ejendo\/lvad173","type":"journal-article","created":{"date-parts":[[2023,12,20]],"date-time":"2023-12-20T15:32:00Z","timestamp":1703086320000},"page":"K17-K20","source":"Crossref","is-referenced-by-count":3,"title":["Pasireotide: potential treatment option for McCune\u2013Albright-associated acromegaly"],"prefix":"10.1093","volume":"190","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7248-7258","authenticated-orcid":false,"given":"Mirela-Diana","family":"Ilie","sequence":"first","affiliation":[{"name":"Inserm U1052, CNRS UMR5286, Claude Bernard Lyon 1 University, Cancer Research Center of Lyon , 69008 Lyon , France"},{"name":"Endocrinology Department, \u201cC.I. Parhon\u201d National Institute of Endocrinology , 011863, Bucharest , Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9517-338X","authenticated-orcid":false,"given":"G\u00e9rald","family":"Raverot","sequence":"additional","affiliation":[{"name":"Inserm U1052, CNRS UMR5286, Claude Bernard Lyon 1 University, Cancer Research Center of Lyon , 69008 Lyon , France"},{"name":"Endocrinology Department, Reference Center for Rare Pituitary Diseases HYPO, \u201cGroupement Hospitalier Est\u201d Hospices Civils de Lyon , 69500 Bron , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6453-8326","authenticated-orcid":false,"given":"Aude","family":"Brac de la Perri\u00e8re","sequence":"additional","affiliation":[{"name":"Endocrinology Department, Reference Center for Rare Pituitary Diseases HYPO, \u201cGroupement Hospitalier Est\u201d Hospices Civils de Lyon , 69500 Bron , France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,12,21]]},"reference":[{"issue":"6","key":"2024011021084222500_lvad173-B1","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1210\/jc.2013-3826","article-title":"Acromegaly and McCune-Albright syndrome","volume":"99","author":"Salenave","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2024011021084222500_lvad173-B2","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/s13023-019-1102-9","article-title":"Best practice management guidelines for fibrous dysplasia\/McCune-Albright syndrome: a consensus statement from the FD\/MAS international consortium","volume":"14","author":"Javaid","year":"2019","journal-title":"Orphanet J Rare Dis."},{"issue":"1","key":"2024011021084222500_lvad173-B3","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1007\/s11102-021-01185-w","article-title":"Real-world experience with pasireotide-LAR in resistant acromegaly: a single center 1-year observation","volume":"25","author":"Stelmachowska-Bana\u015b","year":"2022","journal-title":"Pituitary"},{"issue":"7","key":"2024011021084222500_lvad173-B4","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1210\/jc.2012-1274","article-title":"Somatic GNAS mutation causes widespread and diffuse pituitary disease in acromegalic patients with McCune-Albright syndrome","volume":"97","author":"Vortmeyer","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"2024011021084222500_lvad173-B5","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/s41574-018-0058-5","article-title":"A consensus statement on acromegaly therapeutic outcomes","volume":"14","author":"Melmed","year":"2018","journal-title":"Nat Rev Endocrinol."},{"issue":"19","key":"2024011021084222500_lvad173-B6","doi-asserted-by":"crossref","first-page":"4857","DOI":"10.3390\/cancers13194857","article-title":"Gsp mutation is not a molecular biomarker of long-term response to first-generation somatostatin receptor ligands in acromegaly","volume":"13","author":"Wildemberg","year":"2021","journal-title":"Cancers (Basel)."},{"issue":"11","key":"2024011021084222500_lvad173-B7","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/S2213-8587(22)00244-3","article-title":"Acromegaly: pathogenesis, diagnosis, and management","volume":"10","author":"Fleseriu","year":"2022","journal-title":"Lancet Diabetes Endocrinol"}],"container-title":["European Journal of Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ejendo\/advance-article-pdf\/doi\/10.1093\/ejendo\/lvad173\/54730552\/lvad173.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ejendo\/article-pdf\/190\/1\/K17\/55371501\/lvad173.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ejendo\/article-pdf\/190\/1\/K17\/55371501\/lvad173.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,10]],"date-time":"2024-01-10T21:08:55Z","timestamp":1704920935000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ejendo\/article\/190\/1\/K17\/7486651"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,21]]},"references-count":7,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1,3]]}},"URL":"https:\/\/doi.org\/10.1093\/ejendo\/lvad173","relation":{},"ISSN":["0804-4643","1479-683X"],"issn-type":[{"value":"0804-4643","type":"print"},{"value":"1479-683X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,1]]},"published":{"date-parts":[[2023,12,21]]}}}